Valeo Pharma 2Q results showing 6th consecutive quarter of revenue growth
Vancouver
|
June 14, 2023 01:35 PM Eastern Daylight Time
Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company has once again seen record numbers as it unveils its second-quarter financials. The numbers include the 6th consecutive quarter of revenue growth at $13.6 million, up 184% over 2Q 2022.
Saviuk telling Proactive the number company also saw 6th consecutive quarter of adjusted EBITDA loss reduction at $1.7 million, which is a 53% improvement.
Enerzair and Atectura continue to perform well with total prescriptions for the 12 months ending April 30, 2023 exceeding 45,000, up 654% over April 30, 2022.
Looking ahead, the company projects revenues to exceed $60 million for the year, expecting continued growth in the third quarter.
Contact Details
Proactive Investors
+1 604-688-8158
